diazepam has been researched along with Brain Damage, Chronic in 24 studies
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.
diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.
Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A Phase 3 open-label safety study (NCT02721069) evaluated long-term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters." | 9.41 | Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. ( Biton, V; Carrazana, E; Cascino, GD; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Mauney, W; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| "Theophylline-associated seizures (TAS) are considered a neurologic emergency, as they can sometimes be intractable and difficult to stop with standard treatments such as intravenous administration of diazepam." | 7.74 | First-line therapy for theophylline-associated seizures. ( Yoshikawa, H, 2007) |
| " The present study was undertaken to determine whether diazepam, a potent, centrally penetrating GABAmimetic, alone or in combination with insulin, could mitigate postischemic seizures or regional selective neuronal necrosis and infarction." | 7.68 | Postischemic seizures and necrotizing ischemic brain damage: neuroprotective effect of postischemic diazepam and insulin. ( Auer, RN; Voll, CL, 1991) |
| "A Phase 3 open-label safety study (NCT02721069) evaluated long-term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters." | 5.41 | Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. ( Biton, V; Carrazana, E; Cascino, GD; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Mauney, W; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| "Levetiracetam (LEV) is a structurally novel antiepileptic drug (AED) which has demonstrated a broad spectrum of anticonvulsant activities both in experimental and clinical studies." | 5.34 | Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. ( Bethmann, K; Brandt, C; Fedrowitz, M; Gastens, AM; Glien, M; Löscher, W; Potschka, H; Volk, HA, 2007) |
| "Exposure to organophosphorous (OP) nerve agents such as soman inhibits the critical enzyme acetylcholinesterase (AChE) leading to excessive acetylcholine accumulation in synapses, resulting in cholinergic crisis, status epilepticus and brain damage in survivors." | 3.81 | Alpha-Linolenic Acid-Induced Increase in Neurogenesis is a Key Factor in the Improvement in the Passive Avoidance Task After Soman Exposure. ( Apland, JP; Chen, J; Grunberg, N; Marini, AM; McDonough, J; Pan, H; Piermartiri, TC, 2015) |
| "Theophylline-associated seizures (TAS) are considered a neurologic emergency, as they can sometimes be intractable and difficult to stop with standard treatments such as intravenous administration of diazepam." | 3.74 | First-line therapy for theophylline-associated seizures. ( Yoshikawa, H, 2007) |
| " The present study was undertaken to determine whether diazepam, a potent, centrally penetrating GABAmimetic, alone or in combination with insulin, could mitigate postischemic seizures or regional selective neuronal necrosis and infarction." | 3.68 | Postischemic seizures and necrotizing ischemic brain damage: neuroprotective effect of postischemic diazepam and insulin. ( Auer, RN; Voll, CL, 1991) |
| "Beyond effectiveness for aborting seizure clusters, no data exist on how intermittent rescue therapy may impact the long-term natural course of seizure clusters." | 1.72 | Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters. ( Carrazana, E; Davis, C; Misra, SN; Peters, JM; Rabinowicz, AL; Rao, VR; Sperling, MR, 2022) |
| "Levetiracetam (LEV) is a structurally novel antiepileptic drug (AED) which has demonstrated a broad spectrum of anticonvulsant activities both in experimental and clinical studies." | 1.34 | Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. ( Bethmann, K; Brandt, C; Fedrowitz, M; Gastens, AM; Glien, M; Löscher, W; Potschka, H; Volk, HA, 2007) |
| "Reported are three patients with ictal monoparesis of an arm." | 1.33 | Ictal monoparesis associated with lesions in the primary somatosensory area. ( Aoki, T; Hanakawa, T; Hitomi, T; Ikeda, A; Matsumoto, R; Miki, Y; Shibasaki, H; Shimohama, S; Tomimoto, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (54.17) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Misra, SN | 1 |
| Sperling, MR | 2 |
| Rao, VR | 1 |
| Peters, JM | 1 |
| Davis, C | 1 |
| Carrazana, E | 2 |
| Rabinowicz, AL | 2 |
| Wheless, JW | 1 |
| Miller, I | 1 |
| Hogan, RE | 1 |
| Dlugos, D | 1 |
| Biton, V | 1 |
| Cascino, GD | 1 |
| Liow, K | 1 |
| Vazquez, B | 1 |
| Segal, EB | 1 |
| Tarquinio, D | 1 |
| Mauney, W | 1 |
| Desai, J | 1 |
| Piermartiri, TC | 1 |
| Pan, H | 1 |
| Chen, J | 1 |
| McDonough, J | 1 |
| Grunberg, N | 1 |
| Apland, JP | 1 |
| Marini, AM | 1 |
| Rocha, R | 1 |
| Lisboa, L | 1 |
| Neves, J | 1 |
| García López, M | 1 |
| Santos, E | 1 |
| Ribeiro, A | 1 |
| MACULANS, GA | 1 |
| GALAMBOS, M | 1 |
| Matsumoto, R | 1 |
| Ikeda, A | 1 |
| Hitomi, T | 1 |
| Aoki, T | 1 |
| Hanakawa, T | 1 |
| Miki, Y | 1 |
| Tomimoto, H | 1 |
| Shimohama, S | 1 |
| Shibasaki, H | 1 |
| Engelhorn, T | 1 |
| Weise, J | 1 |
| Hammen, T | 1 |
| Bluemcke, I | 1 |
| Hufnagel, A | 1 |
| Doerfler, A | 1 |
| Brandt, C | 1 |
| Glien, M | 1 |
| Gastens, AM | 1 |
| Fedrowitz, M | 1 |
| Bethmann, K | 1 |
| Volk, HA | 1 |
| Potschka, H | 1 |
| Löscher, W | 1 |
| Yoshikawa, H | 1 |
| Tozer, GM | 1 |
| Penhaligon, M | 1 |
| Nias, AH | 1 |
| Delgado-Escueta, AV | 1 |
| Bajorek, JG | 1 |
| Both, R | 1 |
| Mühlau, G | 1 |
| Neumann, J | 1 |
| Sperschneider, H | 1 |
| Stein, G | 1 |
| Brodtkorb, E | 1 |
| Sand, T | 1 |
| Kristiansen, A | 1 |
| Torbergsen, T | 1 |
| Toone, BK | 1 |
| Fenton, GW | 1 |
| Voll, CL | 1 |
| Auer, RN | 1 |
| Lacombe, DC | 1 |
| Livingston, S | 1 |
| Ferngren, HG | 1 |
| Zavelson, TM | 1 |
| Debusk, FL | 1 |
| Weber, M | 1 |
| Masingue, M | 1 |
| Martin, JY | 1 |
| Tridon, P | 1 |
| Arnould, G | 1 |
| Karno, M | 1 |
| Howell, MC | 1 |
| Rever, GW | 1 |
| Scholl, ML | 1 |
| Trowbridge, F | 1 |
| Rutledge, A | 1 |
| Müller, D | 1 |
| Schulz, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)[NCT02721069] | Phase 3 | 175 participants (Actual) | Interventional | 2016-04-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess the number of participants who received at least one dose of NRL-1 (Valtoco) during the study and comprised the safety population. (NCT02721069)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| NRL-1 5mg | 9 |
| NRL-1 10mg | 54 |
| NRL-1 15 mg | 46 |
| NRL-1 20mg | 54 |
1 review available for diazepam and Brain Damage, Chronic
| Article | Year |
|---|---|
Status epilepticus: mechanisms of brain damage and rational management.
Topics: Anticonvulsants; Brain Damage, Chronic; Diazepam; Electroencephalography; Humans; Phenytoin; Status | 1982 |
1 trial available for diazepam and Brain Damage, Chronic
| Article | Year |
|---|---|
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anticonvulsants; Brain Damage, Chronic; Child; | 2021 |
22 other studies available for diazepam and Brain Damage, Chronic
| Article | Year |
|---|---|
Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters.
Topics: Administration, Intranasal; Adult; Anticonvulsants; Brain Damage, Chronic; Diazepam; Epilepsy; Epile | 2022 |
Alpha-Linolenic Acid-Induced Increase in Neurogenesis is a Key Factor in the Improvement in the Passive Avoidance Task After Soman Exposure.
Topics: alpha-Linolenic Acid; Animals; Antigens, Nuclear; Atropine Derivatives; Avoidance Learning; Brain Da | 2015 |
Neuroborreliosis presenting as acute disseminated encephalomyelitis.
Topics: Brain Damage, Chronic; Cefotaxime; Ceftriaxone; Child, Preschool; Coma; Diazepam; Encephalomyelitis, | 2012 |
COMPARISON OF DIAZEPAM, CHLORPROTHIXENE AND CHLORPROMAZINE IN CHRONIC SCHIZOPHRENIC PATIENTS.
Topics: Alcoholism; Brain; Brain Damage, Chronic; Chlorpromazine; Chlorprothixene; Diazepam; Schizophrenia; | 1964 |
LONG TERM CLINICAL TRIAL WITH DIAZEPAM ON ADULT MENTALLY RETARDED PERSONS.
Topics: Adult; Brain; Brain Damage, Chronic; Diazepam; Drug Therapy; Epilepsy; Epilepsy, Absence; Epilepsy, | 1965 |
Ictal monoparesis associated with lesions in the primary somatosensory area.
Topics: Adult; Arm; Brain Damage, Chronic; Brain Neoplasms; Cerebral Angiography; Cerebral Veins; Diazepam; | 2005 |
Early diffusion-weighted MRI predicts regional neuronal damage in generalized status epilepticus in rats treated with diazepam.
Topics: Animals; Anticonvulsants; Brain; Brain Damage, Chronic; Convulsants; Diazepam; Diffusion; Diffusion | 2007 |
Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats.
Topics: Amygdala; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Brain Damage, Chronic; D | 2007 |
First-line therapy for theophylline-associated seizures.
Topics: Age of Onset; Animals; Anticonvulsants; Barbiturates; Brain Damage, Chronic; Child; Child, Preschool | 2007 |
The use of ketamine plus diazepam anaesthesia to increase the radiosensitivity of a C3H mouse mammary adenocarcinoma in hyperbaric oxygen.
Topics: Adenocarcinoma; Animals; Brain Damage, Chronic; Diazepam; Dose-Response Relationship, Radiation; Fem | 1984 |
[The problem of the so-called dialysis encephalopathy].
Topics: Adolescent; Adult; Brain Damage, Chronic; Dementia; Diazepam; Electroencephalography; Evoked Potenti | 1982 |
Non-convulsive status epilepticus in the adult mentally retarded. Classification and role of benzodiazepines.
Topics: Adult; Aged; Anti-Anxiety Agents; Brain Damage, Chronic; Cerebral Cortex; Diazepam; Drug Therapy, Co | 1993 |
Epileptic seizures induced by psychotropic drugs.
Topics: Adolescent; Adult; Aged; Birth Order; Brain Damage, Chronic; Chlorpromazine; Diazepam; Dose-Response | 1977 |
Postischemic seizures and necrotizing ischemic brain damage: neuroprotective effect of postischemic diazepam and insulin.
Topics: Animals; Brain Damage, Chronic; Brain Ischemia; Diazepam; Insulin; Male; Necrosis; Nervous System; R | 1991 |
Avoiding a malpractice nightmare.
Topics: Adolescent; Brain Damage, Chronic; Diazepam; Humans; Male; Malpractice; Medication Errors; Morphine; | 1990 |
Diagnosis and treatment of childhood myoclonic seizures.
Topics: Adrenal Cortex Hormones; Anticonvulsants; Brain Damage, Chronic; Bromides; Child; Child, Preschool; | 1974 |
Diazepam treatment for acute convulsions in children. A report of 41 patients, three with plasma levels.
Topics: Adolescent; Age Factors; Brain Damage, Chronic; Brain Injuries; Child; Child, Preschool; Diazepam; E | 1974 |
Acute dextropropoxyphene hydrochloride (Darvon) poisoning.
Topics: Adolescent; Brain Damage, Chronic; Dextropropoxyphene; Diazepam; Female; Humans; Nalorphine; Phenoba | 1973 |
[Diagnostic value of the reactivity of E.E.G. foci to diazepam injection. (Statistical study of 327 cases)].
Topics: Adolescent; Adult; Aged; Brain Abscess; Brain Damage, Chronic; Brain Diseases; Brain Edema; Brain In | 1973 |
The care of psychotic patients.
Topics: Adult; Affective Symptoms; Ambulatory Care; Anxiety; Bipolar Disorder; Brain Damage, Chronic; Diazep | 1974 |
Hyperactivity in children: types, diagosis, drug therapy, approaches to management.
Topics: Amphetamine; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chroni | 1972 |
[Clinical and electroencephalographic findings following intravenously administered benzodiazepin (Valium) in children with convulsions and brain damage].
Topics: Adolescent; Adult; Brain Damage, Chronic; Child; Child, Preschool; Diazepam; Drug Tolerance; Electro | 1969 |